Interferon-α and survival in metastatic renal carcinoma: Early results of a randomised controlled trial

Lancet

Volumn 353, Issue 9146, 1999, Pages 14-17

  Ritchie, A W W ^a   Griffiths, G ^b   Parmar, M ^b  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; MEDROXYPROGESTERONE ACETATE; RECOMBINANT ALPHA2B INTERFERON;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; FEMALE; FEVER; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN IRRITATION; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0033514050     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)03544-2     Document Type: Article

References (15)

1. Ritchie A.W.S., de Kernion J.B. The natural history and clinical features of renal carcinoma. Semin Nephrol. 7:1987;131-139.
2. Selli C., Hinshaw W., Woodward B.H., Paulson D.F. Stratification of risk factors in renal cell carcinoma. Cancer. 52:1983;899-903.
3. Ritchie AWS, Oliver RTD. Tumours of the kidney (other than nephroblastoma). In: Peckham M, Pinedo H, Veronesi U. The Oxford textbook of oncology. Oxford University Press, 1995: 1480-98.
4. Fayers P.M., Cook P.A., Machin Det al. On the development of the Medical Research Council Trial of alpha-interferon in metastatic renal carcinoma. Stat Med. 13:1994;2249-2260.
5. De Haes JCJ-M, Van Knippenberg F.C.E., Neijt J.P. Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br J Cancer. 62:1990;1034-1038.
6. Whitehead J. The design and analysis of sequential clinical trials, revised 2nd edn. Wiley: Chichester, 1997.
7. Parmar MKB, Machin D. Survival analysis: a practical approach. Wiley: Chichester, 1995.
8. Steineck G., Strander H., Carbin BEet al. Recombinant leukocyte interferon alpha-2A and medroxyprogesterone in advanced renal cell carcinoma: a randomised trial. Acta Oncol. 29:1990;155-162.
9. Gleave M, Elhilali M, Fradet Y, et al, and the Canadian Urologic Oncology Group. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. N Engl J Med 1998; 338: 1265-71.
10. Pyrhonen S, Salminen E, Lehtonen T, et al. Recombinant interferon alpha-2A with vinablastine vs vinablastine alone in advanced renal cell carcinoma: a phase III study. Proc ASCO 1996; 15: 614 (abstr).
11. Fossa S., Jones M., Johnson Pet al. Interferon-alpha and survival in renal cell cancer. Br J Urol. 76:1995;286-290.
12. Negrier S, Escudier B, Douillard JY, et al. Randomised study of interleukin 2 and interferon with or without 5FU in metastatic renal cell carcinoma. Proc ASCO 1997; 16: 326a (abstr 1161).
13. Atzpodien J, Kirchner H, Franzke A, et al. Results of a randomised clinical trial comparing SC interleukin-2, SC alpha-2A-interferon and IV bolus 5-fluorourcil against oral tamoxifen in progressive metastatic renal cell carcinoma patients. Proc ASCO 1997; 16: 326a (abstr 1164).
14. Henriksson R., Nilsson S., Collen Set al. Survival in renal cell carcinoma - a randomised evaluation of tamoxifen versus interleukin-2, α-interferon (leukocyte) and tamoxifen. Br J Cancer. 77:1998;1311-1317.
15. Negrier S, Escidier B, Lasset C, et al, for the Groupe Français d'Immunotherapie. Recombinant human interleukin-2, recombinant interferon alpha-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 1998; 388: 1272-78.